Phase I study of oxaliplatin in combination with docetaxel and radiotherapy in patients with unresectable or recurrent non-small cell lung cancer (NSCLC).

Trial Profile

Phase I study of oxaliplatin in combination with docetaxel and radiotherapy in patients with unresectable or recurrent non-small cell lung cancer (NSCLC).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2015

At a glance

  • Drugs Docetaxel (Primary) ; Oxaliplatin (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Jan 2010 Actual patient number (4) added as reported by ClinicalTrials.gov.
    • 25 Feb 2008 Status changed from in progress to discontinued.
    • 31 Jan 2008 Status changed from recruiting to in progress according to NCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top